Skip to content

US · BGM · DRUG MANUFACTURERS - SPECIALTY & GENERIC

BGM Group Ltd. (BGM) intrinsic value and stock valuation

$7.22as of 2026-11-21 · Mkt cap 59.61M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BGM Group Ltd. DCF and intrinsic value

InvestorsCraft values BGM with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from BGM’s statements →

BGM Group Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Chengdu, SIC 610200 bgmgroupltd.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$37.9M-5.4% 5y CAGRd
20172025
Net income
-$-19.94M
20172025
Free cash flow
-$-4.44M
20172025
Total equity
$391.9M+68.5% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$37.9M$25.1M$46.5M$64.9M$57.1M
Operating income-$-12.58M-$-560K-$-2.61M$2.1M$2.39M
Net income-$-19.94M-$-1.44M-$-7.78M$1.08M$3.15M
EPSd-$-176.06K-$-199.17K-$-1.08M$149.4K$461.9K
Operating cash flow-$-2.37M$540K$310K$12.7M$350K
Capital expenditure-$-2.07M-$-3.93M-$-3.71M-$-3.26M-$-3.49M
Free cash flow-$-4.44M-$-3.39M-$-3.4M$9.4M-$-3.15M
Total assets$433.8M$53M$51.3M$64.5M$75.4M
Total debt$1.94M$0.00$580K$1.77M$8.03M
Net debt-$-7.88M-$-9.82M-$-6.9M-$-12.55M-$-2.44M
Total equity$391.9M$44.1M$44.4M$55M$56.7M
Cash and short-term investments$10.8M$18.1M$22.4M$14.3M$10.5M
Income statement
20252024202320222021
Revenue$37.9M$25.1M$46.5M$64.9M$57.1M
Cost of revenue$33.1M$21M$44.7M$58.6M$51.5M
Gross profit$4.85M$4.11M$1.75M$6.23M$5.64M
Research and development expenses$670K$1.36M$570K$1.22M$0.00
Selling, general and administrative expenses$16.8M$3.32M$3.79M$2.9M$3.25M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$17.4M$4.68M$4.36M$4.13M$3.25M
Cost and expenses$50.5M$25.7M$49.1M$62.8M$54.7M
Interest income$80K$0.00$100K$20K$0.00
Interest expense$0.00$640K$0.00$0.00$60K
Depreciation and amortization$1.46M$1.24M$1.14M$1.22M$1.2M
Ebitda-$-11.12M$880K-$-1.27M$3.74M$4.15M
Operating income-$-12.58M-$-560K-$-2.61M$2.1M$2.39M
Total other income/expenses, net-$-7.36M-$-1.57M-$-5.29M-$-540K$980K
Income before tax-$-19.94M-$-2.14M-$-7.9M$1.56M$3.36M
Income tax expense$280K-$-620K$220K$190K$260K
Net income-$-19.94M-$-1.44M-$-7.78M$1.08M$3.15M
Weighted average shares outstanding$113.3M$7.23M$7.23M$7.23M$6.82M
Weighted average diluted shares outstanding$113.3M$7.23M$7.23M$7.23M$6.82M
Balance sheet
20252024202320222021
Cash and short-term investments$10.8M$18.1M$22.4M$14.3M$10.5M
Net receivables$17.1M$5.77M$6.35M$4.87M$13.5M
Inventory$23.7M$5.05M$4.99M$8.88M$12.5M
Total current assets$51.6M$29.8M$34.5M$30M$40.4M
Property, plant and equipment, net$15.1M$14.9M$12.7M$12.3M$11.5M
Goodwill and intangible assets$355.3M$4.54M$3.42M$1.73M$1.93M
Long-term investments$11.5M$3.36M$610K$20.1M$21M
Total non-current assets$382.3M$23.2M$16.8M$34.5M$35M
Total assets$433.8M$53M$51.3M$64.5M$75.4M
Accounts payable$6.56M$4.13M$3.59M$5.29M$6.64M
Short-term debt$1.86M$0.00$550K$1.7M$7.92M
Deferred revenue$3.14M$570K$1.11M$680K$2.84M
Total current liabilities$41.6M$8.78M$6.66M$9.18M$18.2M
Long-term debt$80K$0.00$20K$70K$110K
Deferred revenue, non-current$0.00$130K$220K$310K$400K
Total non-current liabilities$80K$130K$250K$380K$510K
Capital lease obligations$80K$0.00$100K$100K$160K
Total liabilities$41.7M$8.91M$6.91M$9.56M$18.7M
Common stock$1.67M$60K$60K$60K$60K
Retained earnings-$-15.78M$4.35M$5.9M$15.5M$14.7M
Accumulated other comprehensive income (loss)$5.97M$1.92M$430K$1.07M$3.71M
Total equity$391.9M$44.1M$44.4M$55M$56.7M
Total investments$12.5M$11.7M$15.6M$20.1M$21M
Total debt$1.94M$0.00$580K$1.77M$8.03M
Net debt-$-7.88M-$-9.82M-$-6.9M-$-12.55M-$-2.44M
Cash flow statement
20252024202320222021
Net income-$-19.94M-$-1.52M-$-8.12M$1.37M$3.11M
Depreciation and amortization$1.46M$1.24M$1.14M$1.22M$1.2M
Stock-based compensation$0.00$0.00$0.00$20K$0.00
Change in working capital-$-3.19M$790K$1.11M$8.75M-$-3.67M
Accounts receivable-$-2.97M$1.33M-$-2.89M$9.77M-$-160K
Inventory$850K$960K$3.4M$2.23M$50K
Accounts payable-$-1.83M$380K-$-1.62M-$-810K$2.02M
Net cash provided by operating activities-$-2.37M$540K$310K$12.7M$350K
Investments in property, plant and equipment-$-2.19M-$-2.85M-$-1.85M-$-3.23M-$-3.49M
Acquisitions, net$2.39M$0.00-$-30K$0.00-$-710K
Net cash used for investing activities-$-160K$980K-$-4.74M-$-3.26M-$-24.2M
Common stock issued$0.00$0.00$0.00$0.00$23.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00-$-1.79M$0.00$0.00
Net cash used for financing activities$2.62M-$-490K-$-2.92M-$-5.94M$24M
Net change in cash$0.00$2.34M-$-7.5M$2.37M$740K
Cash at end of period$9.82M$9.82M$7.48M$15M$12.6M
Operating cash flow-$-2.37M$540K$310K$12.7M$350K
Capital expenditure-$-2.07M-$-3.93M-$-3.71M-$-3.26M-$-3.49M
Free cash flow-$-4.44M-$-3.39M-$-3.4M$9.4M-$-3.15M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BGM Group Ltd.

        Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.

        CEO
        Chen Xin
        Employees
        298
        Beta
        1.79

        Explore

        Frequently asked questions

        What is the intrinsic value of BGM Group Ltd. (BGM)?

        BGM Group Ltd. (BGM) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BGM undervalued?

        BGM trades at a price of $7.22 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.